Patients who have been diagnosed with Type 2 diabetes may or may not be familiar with medications such as Januvia, Janumet and Sitagliptin. They also may or may not also be familiar with the severe side-effects some patients encounter from the use of these drugs.
Pancreatitis is one of the serious side effects linked to this Januvia. Prescribed to maintain the levels of blood sugar in Type 2 diabetes patients,Januvia is generating a significant amount of attention through the FDA’s Adverse Event Reporting System. Some statistics stemming from this information show that 66% of Januvia, Janumet and Sitagliptin cases required hospitalization for pancreatitis, 21% of cases showed pancreatitis developed within 30 days of taking Januvia, and 53% of cases were resolved once medication use was discontinued.
If you have developed Pancreatitis from the use of Januvia contact us today,we may be able to help. The claim evaluation is free and with most claims of this type, there is no cost up-front cost for legal fees. The attorneys in our network handle most claims on a contingency basis. There are statutes surrounding the time you are able to file a claim so contact us today!
Defectivemedications@gmail.com
Tuesday, August 14, 2012
Wednesday, July 18, 2012
First weight loss medication to win FDA approval in 13 years…..
Last month the FDA’s Endicrinologic and Metabolic Drug Advisory Committee approved Arena Pharmaceutical’s new weight loss drug Belviq(lorcaserin) in an 18-4 vote.
Lorcaserin, which will be marketed under the trade marked name Belviq, is a weight loss medication developed to battle obesity. It acts as an appetite suppressant which is essentially effective by causing patients to feel less hunger sensations. Ultimately the body ingests less food and thus less calories, resulting in weight reduction. The drug has been approved for patients with a Body Mass Index (BMI) over 30 or for those with a BMI of at least 27 suffering from additional conditions such as high blood pressure and diabetes.
Belviq/Lorcaserin is the first drug of its kind to gain approval in 13 years, potentially paving the way for a handful of others, which may or may not be targeted at certain factions of the obese population. Considering the obesity rate of the U.S. alone, a prescription weight loss supplement such as this could potentially become a sensation. Arena Pharmaceuticals, the manufacturer of Belviq/Lorcaserin, and its investors are expecting significant profits, especially upon approval with the European Union.
Lorcaserin, which will be marketed under the trade marked name Belviq, is a weight loss medication developed to battle obesity. It acts as an appetite suppressant which is essentially effective by causing patients to feel less hunger sensations. Ultimately the body ingests less food and thus less calories, resulting in weight reduction. The drug has been approved for patients with a Body Mass Index (BMI) over 30 or for those with a BMI of at least 27 suffering from additional conditions such as high blood pressure and diabetes.
Belviq/Lorcaserin is the first drug of its kind to gain approval in 13 years, potentially paving the way for a handful of others, which may or may not be targeted at certain factions of the obese population. Considering the obesity rate of the U.S. alone, a prescription weight loss supplement such as this could potentially become a sensation. Arena Pharmaceuticals, the manufacturer of Belviq/Lorcaserin, and its investors are expecting significant profits, especially upon approval with the European Union.
Lorcaserin: The new diet drug: A blessing or a curse?
Potential problems with Belviq/Lorcaserin….
Belviq/Lorcaserin has picked up some scars along the road to approval. Although side effects reported in association with its use appear tobe mild and for the most tolerable, it had been previously rejected by the FDAon the grounds that its safety profile had not been sufficiently explored. This rejection was in 2009.
It works similar to the now banned drug, Fenfluramine, which was the culprit in a massive amount of heart related injuries such as cardiacfibrosis and cardiac valvulopathy and marketed under the name Fen-Phen. Arena claims the drug is much more selective than Fenfluramine, so the risks are significantly decreased.
In animal studies, reports show that there were occasions of tumors that grew in the mammary tissue of rats. This also remains a concern, a concern that has prompted the FDA to issue a warning to the maker despite approving the drug in an 18-4 vote. Substantial long-term studies are not available and with the approval of Belviq/Lorcaserin, other drugs, with scars of their own, one particularly pertaining to complications with heart valves are vying for a spot in the market. The obesity drug market is still rather unexplored which leaves additional speculation to come.
Belviq/Lorcaserin has picked up some scars along the road to approval. Although side effects reported in association with its use appear tobe mild and for the most tolerable, it had been previously rejected by the FDAon the grounds that its safety profile had not been sufficiently explored. This rejection was in 2009.
It works similar to the now banned drug, Fenfluramine, which was the culprit in a massive amount of heart related injuries such as cardiacfibrosis and cardiac valvulopathy and marketed under the name Fen-Phen. Arena claims the drug is much more selective than Fenfluramine, so the risks are significantly decreased.
In animal studies, reports show that there were occasions of tumors that grew in the mammary tissue of rats. This also remains a concern, a concern that has prompted the FDA to issue a warning to the maker despite approving the drug in an 18-4 vote. Substantial long-term studies are not available and with the approval of Belviq/Lorcaserin, other drugs, with scars of their own, one particularly pertaining to complications with heart valves are vying for a spot in the market. The obesity drug market is still rather unexplored which leaves additional speculation to come.
Wednesday, June 27, 2012
Settlement on Yaz & Yasmin
Last month it was reported from Bloomberg News that Bayer AG, the largest drug manufacturer in Germany, agreed to at least a $100 million settlement to resolve about 500 lawsuits involving their contraceptive medications, Yaz and Yasmin. The settlement is a result of a few years of litigation set forth by women who claimed Yaz and Yasmin were the cause their Deep Vein Thrombosis or Pulmonary Embolism.
Approximately $220,000 per case is the reported amount required by Bayer to settle each case claiming Yaz and Yasmin as the cause of blood clots. Sometimes fatal, the clots may also cause heart attacks and strokes.
If you or a loved one suffered an injury as a result of taking Yaz, Yasmin or Ocella, you may be entitled to compensation. Reported injuries associated with these medications have been heart attacks, strokes, gall bladder disease, pulmonary embolisms,and deep vein thrombosis. The time to file a claim is ending soon so contact us now for a free claim evaluation at defectivemedications@gmail.com
"LIKE" us on facebook http://www.facebook.com/DefectiveMedications
Approximately $220,000 per case is the reported amount required by Bayer to settle each case claiming Yaz and Yasmin as the cause of blood clots. Sometimes fatal, the clots may also cause heart attacks and strokes.
If you or a loved one suffered an injury as a result of taking Yaz, Yasmin or Ocella, you may be entitled to compensation. Reported injuries associated with these medications have been heart attacks, strokes, gall bladder disease, pulmonary embolisms,and deep vein thrombosis. The time to file a claim is ending soon so contact us now for a free claim evaluation at defectivemedications@gmail.com
"LIKE" us on facebook http://www.facebook.com/DefectiveMedications
Monday, June 18, 2012
Pradaxa and Internal Bleeding
Pradaxa, a blood thinning medication prescribed to treat blood clots, has come under fire for allegations that it is causing serious internal bleeding events in patients. In some cases, the bleeding events have resulted in death as there is no reversal agent to counteract the drug. Over 200 deaths have been reported in direct relation to the use of Pradaxa. Unlike Warfarin and other blood thinning medications there is no protocol to resume immediate clotting when using Pradaxa in such circumstances.
Bleeding events can include the following:
-Gastrointestinal Bleeding
-Spontaneous Internal Bleeding
-Hemorrhagic Stroke (Bleeding on the brain.)
-Excessive bleeding after trauma.
A recent study has also linked Pradaxa use to an increased risk of heart attack and acute coronary syndrome by 33% over the use of Warfarin and placebos. Lawsuits have already been filed and many more are pending.The lawyers filing suits allege that the injured plaintiffs have experienced severe side-effects as a result of using Pradaxa, and were unaware of these certain risks.
Like us on facebook at http://www.facebook.com/DefectiveMedications
Bleeding events can include the following:
-Gastrointestinal Bleeding
-Spontaneous Internal Bleeding
-Hemorrhagic Stroke (Bleeding on the brain.)
-Excessive bleeding after trauma.
A recent study has also linked Pradaxa use to an increased risk of heart attack and acute coronary syndrome by 33% over the use of Warfarin and placebos. Lawsuits have already been filed and many more are pending.The lawyers filing suits allege that the injured plaintiffs have experienced severe side-effects as a result of using Pradaxa, and were unaware of these certain risks.
Like us on facebook at http://www.facebook.com/DefectiveMedications
Yaz Side Effects Lawsuit
Women who have suffered from any of the following injuries may have a claim and be entitled to financial compensation.
*Pulmonary Embolism
*Deep Vein Thrombosis
*Heart Attack
*Stroke
*Gallbladder Disease
Lawsuits that have already been filed allege that Bayer Pharmaceuticals, the maker of Yaz and Yasmin, did not conduct sufficient research on the medication and failed to perform a recall after post-marketing reports identified a risk of life threatening conditions. The suits also allege that Bayer Pharmaceuticals insufficiently warned of the risks of Yaz and Yasmin in an effort produce comfort among consumers.
The U.S. Food and Drug Administration (FDA) Adverse Events reporting system indicated serious side effects of using Yaz, Yasmin and Ocella including but not limited to heart arrhythmias, stroke, gallbladder problems, blood clots, embolisms and sudden death following the use of the medications.
Drospirenone, a type of progestin used in the oral contraceptives Yaz and Yasmin, is a significant contributing factor in the injuries associated with the medications. It can cause elevated levels of potassium which can lead to serious heart conditions and other concerns.
We are reviewing claims of injuries associated with Yaz, Yasmin and Ocella. If you or a loved has suffered any of the listed side effects contact us today for a free claim evaluation.
Like us on facebook at http://www.facebook.com/DefectiveMedications
*Pulmonary Embolism
*Deep Vein Thrombosis
*Heart Attack
*Stroke
*Gallbladder Disease
Lawsuits that have already been filed allege that Bayer Pharmaceuticals, the maker of Yaz and Yasmin, did not conduct sufficient research on the medication and failed to perform a recall after post-marketing reports identified a risk of life threatening conditions. The suits also allege that Bayer Pharmaceuticals insufficiently warned of the risks of Yaz and Yasmin in an effort produce comfort among consumers.
The U.S. Food and Drug Administration (FDA) Adverse Events reporting system indicated serious side effects of using Yaz, Yasmin and Ocella including but not limited to heart arrhythmias, stroke, gallbladder problems, blood clots, embolisms and sudden death following the use of the medications.
Drospirenone, a type of progestin used in the oral contraceptives Yaz and Yasmin, is a significant contributing factor in the injuries associated with the medications. It can cause elevated levels of potassium which can lead to serious heart conditions and other concerns.
We are reviewing claims of injuries associated with Yaz, Yasmin and Ocella. If you or a loved has suffered any of the listed side effects contact us today for a free claim evaluation.
Like us on facebook at http://www.facebook.com/DefectiveMedications
Wednesday, June 13, 2012
Yaz and Yasmin Lawsuit
Bayer settled over 600 lawsuits alleging injuries were sustained from its popular oral contraceptives Yaz and Yasmin. The injuries include but are not limited togall bladder disease, stroke, blood clots, embolisms, and in severe cases death.
Inits 2011 Annual Report, Bayer admits to settling 70 Yaz and Yasmin lawsuits. According to the report, attorneys for the plaitiffs and Bayer reached agreements, without admission of liability, to settle the 70 claims.
The initial bellwether trial, scheduled to commence January 9, 2012, has been delayed until further order from the court. Judge Herndon, the judge overseeing the litigation, would like to allow the parties additional time to settle a near 6,000 lawsuits related to Yaz and Yasmin. The suits claim the drugs are responsible for injuries to patients that include pulmonary embolisms (PE), deep vein thrombosis (DVT), and strokes.
Subscribe to:
Posts (Atom)